Brain disorders (Amsterdam, Netherlands)最新文献

{"title":"Neuroprotective mechanisms and ameliorative activities of quercetin in cisplatin-induced cerebellum neurotoxicity in rat models","authors":"Sunday Aderemi Adelakun ,&nbsp;Babatunde Ogunlade ,&nbsp;Julius Akomaye Aniah ,&nbsp;Oladipupo Nifemi Akinyemi","doi":"10.1016/j.dscb.2024.100166","DOIUrl":"10.1016/j.dscb.2024.100166","url":null,"abstract":"<div><div>Cisplatin (CP) is a highly effective antitumor agent, but its clinical use is limited due to critical adverse reactions including neurotoxicity. Quercetin (QC) is a naturally occurring phytochemical with promising bioactive effects. This study investigated the Neuroprotective mechanisms and ameliorative activities of quercetin in cisplatin-induced cerebellum neurotoxicity in rat models.</div><div>The rats were randomly divided into five groups of six (<em>n</em> = 6) rats. Group A, served as control. Group B, received a single dose of 10 mg/kg body weight (bwt) of CP (i.p.) on the first day. Group C received 30 mg/kg bwt of QC. Group D received a single dose of 10 mg/kg bwt CP on the first day followed by 30 mg/kg bwt of QC. Group E received 30 mg/kg bwt of QC per day followed by a single dose of 10 mg/kg bwt of CP on the last day. The treatment lasted for 35 days after which the novel-object recognition memory test (NORT) was used to assess non-spatial memory function. Brain neurochemical status was assessed and brain tissues were processed for histology.</div><div>Quercetin increased weight loss and cognitive performance in CP-treated rats by enhancing the exploration of unfamiliar objects. Quercetin protects the brain from CP-mediated alterations in oxidative status, as well as brain metabolic enzyme indicators. It also decreased IL-6, IL-1, and TNF-α, and NF-ĸB expression, restored brain metabolic enzyme activities, increased neurotransmitters, and prevented neuromorphological alterations.</div><div>In conclusion, quercetin protects rats’ brains against CP-induced cerebellum neurotoxicity via oxidative stress inhibition and down-regulation of inflammation.</div></div>","PeriodicalId":72447,"journal":{"name":"Brain disorders (Amsterdam, Netherlands)","volume":"16 ","pages":"Article 100166"},"PeriodicalIF":0.0,"publicationDate":"2024-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142421023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel approaches targeting α-Synuclein for Parkinson's Disease: Current progress and future directions for the disease-modifying therapies","authors":"David Baggett ,&nbsp;Alex Olson ,&nbsp;Mayur S. Parmar","doi":"10.1016/j.dscb.2024.100163","DOIUrl":"10.1016/j.dscb.2024.100163","url":null,"abstract":"<div><div>Parkinson's Disease (PD) is a common and debilitating neurodegenerative disorder affecting millions worldwide. The hallmark pathological feature of PD is the accumulation and aggregation of α-Synuclein (α-Syn), a protein involved in synaptic function and neuronal survival. The formation of α-Syn aggregates, also known as Lewy bodies and Lewy neurites, leads to neuronal dysfunction and death, resulting in PD's characteristic motor and non-motor symptoms. Current treatments for PD are mainly symptomatic and do not address the underlying cause of the disease. Therefore, there is an urgent need for disease-modifying therapies that can prevent, slow, or reverse the progression of PD by targeting α-Syn aggregation. In this review, we summarize the current status of pharmacological interventions that aim to reduce α-Syn levels in PD and other Synucleionopathies by various mechanisms, such as inhibiting α-Syn aggregation, enhancing α-Syn clearance, modulating α-Syn-related enzymes, or blocking α-Syn transmission. We focus on agents that have reached phase 1 or 2 clinical trials and provide an overview of their preclinical and clinical data and their safety and efficacy profiles. While fewer candidates have shown positive results in clinical trials, they are awaiting further evaluation in larger and longer-term studies. None of the placebo-controlled, blind trials, except Prasinezumab, have demonstrated efficacy. These novel disease-modifying therapy approaches can potentially change the landscape of PD treatment and improve the quality of life for PD patients.</div></div>","PeriodicalId":72447,"journal":{"name":"Brain disorders (Amsterdam, Netherlands)","volume":"16 ","pages":"Article 100163"},"PeriodicalIF":0.0,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142323030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute intermittent porphyria: A case report with an unlisted HMBS gene variant (c.345–2A>C)","authors":"Julien Lerusse ,&nbsp;Dominique Dive ,&nbsp;François Charles Wang","doi":"10.1016/j.dscb.2024.100160","DOIUrl":"10.1016/j.dscb.2024.100160","url":null,"abstract":"<div><p>We report a case of acute intermittent porphyria in a 19-year-old patient, linked to an unlisted variant of the gene encoding hydroxymethylbilane synthase c.345–2A&gt;C. Given the very low prevalence of porphyria in the general population, diagnosis is rarely made initially and may mainly mimic Guillain-Barré syndrome. Considering this, we provide an overview addressing various ways the disease manifests, paraclinical investigations, pathophysiology, and available therapeutic options. Specifically, human heme therapy in the case of acute crises is nearly unanimous in the literature. However, there is no consensus on the management between crises if the current first line choice treatment, namely givosiran, is not accessible. We report the clinical follow-up proposed for this patient.</p></div>","PeriodicalId":72447,"journal":{"name":"Brain disorders (Amsterdam, Netherlands)","volume":"15 ","pages":"Article 100160"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666459324000453/pdfft?md5=16e5886fcab133d87dd497249eef398f&pid=1-s2.0-S2666459324000453-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142150385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High-intensity body weight interval training modifies neurochemistry in AD disease: Preliminary data from a randomized control trial","authors":"Vernon Furtado-da-Silva ,&nbsp;Domingos Edno Castro Ribeiro ,&nbsp;Célio José Borges ,&nbsp;Ivete de Aquino Freire ,&nbsp;Angeliete Garces Militão ,&nbsp;Daniel Delani ,&nbsp;Luis Gonzaga de Oliveira Gonçalves ,&nbsp;João Rafael Valentim-Silva","doi":"10.1016/j.dscb.2024.100159","DOIUrl":"10.1016/j.dscb.2024.100159","url":null,"abstract":"<div><h3>Background</h3><p>Alzheimer's disease (AD) is an incurable condition characterized by cognitive and neurochemical impairments, necessitating the exploration of alternative interventions. Physical exercise shows promise, but the effects of high-intensity protocols on the neurochemical aspects of AD-related neurodegeneration remain poorly explored.</p></div><div><h3>Objective</h3><p>This study examines the effects of high-intensity body weight interval training (PMED) on brain-derived neurotrophic factor (BDNF) and phosphorylated-TAU protein (p-TAU) in AD disease.</p></div><div><h3>Methods</h3><p>Thirty-four elderly individuals diagnosed with AD disease were divided into two groups of 17 subjects: GCP, which participated in PMED (30 min at 80–90 % of maximal cardiac frequency three times per week), and GCS, which had no interventions. Pre- and post-measurements of BDNF and p-TAU were conducted.</p></div><div><h3>Results</h3><p>The GCS group showed no changes in his neurochemical factors (<em>p</em> &gt; 0.05). In contrast, the GCP group experienced increased BDNF levels and decreased p-TAU blood concentrations (<em>p</em> &lt; 0.0001 for both).</p></div><div><h3>Conclusions</h3><p>PMED increased BDNF and reduced p-TAU concentrations, improving neurochemistry in AD disease. This can open an avenue of new interventions using high-intensity body weight interval training, including, in home base programs, which can be an advantage to engagement.</p></div>","PeriodicalId":72447,"journal":{"name":"Brain disorders (Amsterdam, Netherlands)","volume":"15 ","pages":"Article 100159"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666459324000441/pdfft?md5=ebc5439dd2afab8ee51fef73156e8ca0&pid=1-s2.0-S2666459324000441-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142150384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Decision making for decompressive craniectomy (DC) in patients with malignant middle cerebral artery infarction (mMCAI) based on inclusion criteria of clinical studies: A systematic review","authors":"Ali Mulhem","doi":"10.1016/j.dscb.2024.100161","DOIUrl":"10.1016/j.dscb.2024.100161","url":null,"abstract":"<div><p>The introduction of DC as therapy for mMCAI reduced the mortality rate. We aimed to summarise the inclusion criteria in studies of DC to provide a guidance of patients selection.</p><p>We searched 7 databases from inception till 31st December 2021 with an updated search on 25th June 2024. We included studies if they compared patients with mMCAI who underwent DC in addition to medical treatment and patients managed with medical care alone.</p><p>32 studies were published between 1995 and 2022. All studies stated that infarction of at least &gt;50 % of MCA territory was the main inclusion criterion. The mean age of patients was 53 but varied from 18 to 89. Most studies (<em>n</em> = 27) included patients &gt;60 years. Clinical inclusion criteria were NIHSS&gt;15, used by 15 studies, and GCS ≥ 6, used by 9 studies. Radiological criteria were MLS ≥ 5 mm (<em>n</em> = 6), and signs of brain herniation (<em>n</em> = 8). The stroke duration was an inclusion criterion in 17 studies; it varied from 6 h to 96 h, with 10 studies limiting the time window to &lt;48 h since the infarct onset. Lastly, 23 studies excluded patients with previous disabilities measured as mRS &gt; 1 or patients with signs of brain death.</p><p>Inclusion criteria for mMCAI to undergo DC varied among studies; however, there were many similarities, namely a large volume of infarction, wide age range without exclusion of older patients, less severe neurological status as assessed with NIHSS or GCS, no previous physical disability, clear midline shift on imaging and the first two days since the onset of stroke.</p></div>","PeriodicalId":72447,"journal":{"name":"Brain disorders (Amsterdam, Netherlands)","volume":"15 ","pages":"Article 100161"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666459324000465/pdfft?md5=9f7a0e7475a65578c9f461dd43ccfb96&pid=1-s2.0-S2666459324000465-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142150453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent developments in selective therapeutic targeting of functionalized nanomaterials to neurovascular units in overcoming the gaps in neurovascular therapy","authors":"Sakshi Goswami ,&nbsp;Nickolay K. Isaev ,&nbsp;Alla B. Salmina ,&nbsp;Suresh Vir Singh Rana ,&nbsp;Sergey N. Illarioshkin ,&nbsp;Yeshvandra Verma","doi":"10.1016/j.dscb.2024.100162","DOIUrl":"10.1016/j.dscb.2024.100162","url":null,"abstract":"<div><p>Neurodegenerative disorders are difficult to treat because of natural barrier in the brain. Moreover, neurovascular units seem to be essential targets/mediators of the nervous system cytoprotective effects. Functionalized nanomaterials have gained significant prominence in the medical domain due to their extensive utilization in targeted drug delivery and therapeutics within the neurovascular system. Their remarkable potential in neurovascular therapy has been demonstrated, highlighting their effectiveness in this field. A systematic summary of the specific applications and limitations of functionalized nanomaterials in the targeted delivery system is essential for developing smart therapies to overcome the gaps in neurovascular therapy for the treatment of neurological disorders. The objective of present article was to highlight the advancements in recent therapies support the potential role of functionalized nanomaterials to tackle the difficulties in targeted delivery systems for neurodegenerative disorders. We review the role of functionalized nanomaterials as therapeutics within the neurovascular units and their potential to lead to more sophisticated and smart treatment techniques despite some obstacles, given to the patients of neurological disorders, particularly when paired with multimodal drugs who are likely to benefit from cytoprotection. This review also addresses the current understanding, gaps, and issues to be resolved.</p></div>","PeriodicalId":72447,"journal":{"name":"Brain disorders (Amsterdam, Netherlands)","volume":"15 ","pages":"Article 100162"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666459324000477/pdfft?md5=bb69e994fe8a72f4a7ef8ad9324fcc86&pid=1-s2.0-S2666459324000477-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142157532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The association between type 2 diabetes mellitus and Parkinson's disease; a systematic review and meta-analysis","authors":"Maria Anna Bantounou ,&nbsp;Khalisah Shoaib ,&nbsp;Adele Mazzoleni ,&nbsp;Harsh Modalavalasa ,&nbsp;Niraj Kumar ,&nbsp;Sam Philip","doi":"10.1016/j.dscb.2024.100158","DOIUrl":"10.1016/j.dscb.2024.100158","url":null,"abstract":"<div><p>Type 2 Diabetes Mellitus (T2DM) may be a novel risk factor for Parkinson's Disease (PD). Due to the mechanistic plausibility and conflicting reports in clinical studies of an association between PD and T2DM, we conducted a systematic review and meta-analysis to further investigate the relationship between the two conditions. We searched EMBASE, MEDLINE, and Scopus databases from database inception to July 8, 2022 for English-language articles that explored the risk relationship between T2DM and PD. R project was used to estimate the pooled odds ratio (OR) and 95 % confidence interval (CI) (PROSPERO registration number: CRD42022353804). Seventeen observational studies were analysed, including a total of 32,551,133 participants, of whom 48,609 (0.15 %) were diagnosed with both T2DM and PD. The analysis revealed that T2DM increased the likelihood of PD development [OR = 1.59 (CI; 1.30, 1.95)], the odds were not significantly influenced by age, sex, or diabetes duration. The odds of developing PD were higher in participants with T2DM complications compared to those without complications [OR = 1.62 (CI; 1.24, 2.12)]. T2DM was associated with more severe motor decline evidenced by higher Unified Parkinson's Disease Rating Scale scores, but not for developing cognitive impairment. All outcomes were assessed to be of very low certainty, due to high risk of bias and significant heterogeneity. Further studies are required to understand this relationship between T2DM and PD, particularly with a focus on exploring the potential of repurposing antidiabetic medications as disease-modifying treatments for PD.</p></div>","PeriodicalId":72447,"journal":{"name":"Brain disorders (Amsterdam, Netherlands)","volume":"15 ","pages":"Article 100158"},"PeriodicalIF":0.0,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S266645932400043X/pdfft?md5=0b0a0a1bfe00de6bbe60633230e6398d&pid=1-s2.0-S266645932400043X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141984953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cytotoxic lesions of the corpus callosum due to FOLFIRINOX chemotherapy","authors":"Mafalda Soares ,&nbsp;Sara Rosa ,&nbsp;Sofia Bettencourt ,&nbsp;Rita Ferreira ,&nbsp;Mariana Sardinha ,&nbsp;Margarida Dias ,&nbsp;Bruno Cunha","doi":"10.1016/j.dscb.2024.100157","DOIUrl":"10.1016/j.dscb.2024.100157","url":null,"abstract":"<div><p>Cytotoxic lesions of the corpus callosum (CLOCCs) have gained attention due to their various clinical presentations and potential neurotoxic etiologies. The splenium connects visual areas across cerebral hemispheres and plays a vital role in processing visual cues. Previously, these reversible lesions were associated with mild encephalitis or encephalopathy, but in fact, they belong to a broader spectrum encompassing various syndromes. Often triggered by cytokinopathy, CLOCCs are usually hyperintense on T2/FLAIR, non-enhancing and show diffusion restriction.</p><p>A 47-year-old woman with pancreatic ductal adenocarcinoma undergoing FOLFIRINOX chemotherapy (folinic acid, fluorouracil, irinotecan and oxaliplatin) developed strabismus and dizziness two days post-chemo. Neurological examination identified an incomplete wall-eyed bilateral internuclear ophthalmoplegia – a rare finding. Neuroimaging revealed restricted diffusion involving the splenium of the corpus callosum, discreetly hyperintense on T2/FLAIR, non-enhancing and without significant associated mass effect. Neurotoxicity and encephalopathy related to 5-FU were considered, leading to hospitalization. Ammonia levels and liver function were normal. Following discontinuation of the drug, the patient had a fast full clinical recovery and a follow-up MRI confirmed total resolution of splenium lesions. Posteriorly, she completed six cycles of Gemcitabine, uneventfully.</p><p>This case highlights the spectrum of CLOCCs and the potential neurotoxicity of chemotherapy agents, specifically 5-FU. The patient's unique presentation of bilateral internuclear ophthalmoplegia, enriches the understanding of its manifestations. This case emphasizes the need to consider toxic etiologies alongside conventional triggers. Further research into the neurological effects of chemotherapeutic agents, especially 5-FU, on the corpus callosum is crucial.</p></div>","PeriodicalId":72447,"journal":{"name":"Brain disorders (Amsterdam, Netherlands)","volume":"15 ","pages":"Article 100157"},"PeriodicalIF":0.0,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666459324000428/pdfft?md5=4aed6173aced0bc46ed5f6aeeec18600&pid=1-s2.0-S2666459324000428-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142012181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rheumatoid meningitis sine arthritis: An emerging cause of isolated pachymeningitis and leptomeningitis with typical features","authors":"Mickael Bonnan ,&nbsp;Matthieu Faillot ,&nbsp;Adrien Carle ,&nbsp;Nicolas Defoor ,&nbsp;Juliette Rocca ,&nbsp;Gédéon Balley ,&nbsp;Franck Bielle ,&nbsp;Dominique Cazals-Hatem ,&nbsp;Fahima Fernani ,&nbsp;Carole Henry","doi":"10.1016/j.dscb.2024.100156","DOIUrl":"10.1016/j.dscb.2024.100156","url":null,"abstract":"<div><h3>Background and purpose</h3><p>Rheumatoid meningitis (RM) is a meningeal inflammation rarely occurring during the course of rheumatoid arthritis (RA). Anti-citrullinated protein antibodies (ACPA), which are highly specific biomarkers of RA, may allow RM sine arthritis (RMSA) to be diagnosed as an extra-articular early lesion of RA. MRI typically displays pachymeningitis and/or leptomeningitis predating convexity, and CSF diffusivity is focally restricted. Blood ACPA is a strong clue and intrathecal synthesis of ACPA is characteristic although rarely reported.</p></div><div><h3>Methods</h3><p>We report two cases of RMSA that were confirmed by meningeal biopsy and intrathecal synthesis.</p></div><div><h3>Results</h3><p>RMSA abated after steroids alone or associated with rituximab. No arthritis occurred during the follow-up.</p></div><div><h3>Conclusion</h3><p>RM can occur in the absence of RA.</p></div>","PeriodicalId":72447,"journal":{"name":"Brain disorders (Amsterdam, Netherlands)","volume":"15 ","pages":"Article 100156"},"PeriodicalIF":0.0,"publicationDate":"2024-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666459324000416/pdfft?md5=46e95e9ce678e516d764b3fb67fad806&pid=1-s2.0-S2666459324000416-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141838371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Virtual reality intervention for improving cognitive function in post-stroke patient: A systematic review and meta-analysis","authors":"Hendry Gunawan ,&nbsp;Irene Gunawan ,&nbsp;Yetty Hambarsari ,&nbsp;Rivan Danuaji ,&nbsp;Baarid L Hamidi ,&nbsp;Benedictus Benedictus","doi":"10.1016/j.dscb.2024.100152","DOIUrl":"10.1016/j.dscb.2024.100152","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;p&gt;Stroke is one of the leading causes of disability worldwide. In the next few decades, post-stroke disability is expected to increase by up to 35% due to the current increase in cerebrovascular risk factors. Disabilities caused by stroke can include cognitive and motor impairment. The current research on post-stroke rehabilitation mostly focuses on the motor disability aspect. Recently, the International Stroke Recovery and Rehabilitation Alliance 2018 stated that post-stroke cognitive impairment (PSCI) is one of the research priorities. Following recent technological developments, virtual reality (VR)-based therapy is now emerging. This technology is attractive because it can simulate various activities in a safe environment. However, research on VR for post-stroke patients still does not have specific guidelines that must be followed, so the types of interventions carried out through VR still vary. Therefore, this study aims to assess how the benefits of using VR in improving cognitive function in post-stroke patients and what VR interventions show the greatest benefits.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Method&lt;/h3&gt;&lt;p&gt;This research is a systematic review and meta-analysis conducted based on Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) 2020 guidelines. The data used for this study were obtained from PubMed, Scopus, and Science Direct databases. The search conducted in this systematic review was done without any year restriction. The studies included were randomized controlled trials (RCTs) and pilot RCTs.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;p&gt;This systematic review included eight studies involving 313 participants in total. All studies were used for the meta-analysis, with five, four, and six studies used in the rote memory function, executive function, and general cognitive analyses, respectively. Assessment using the trail making test (TMT) on the TMT-A test related to rote memory function (MD = -26.43, 95% CI -43.18 – -9.68, &lt;em&gt;P&lt;/em&gt; = 0.002) and TMT-B test related to executive function (MD = -59.23, 95% CI -103.21 – -15.25, &lt;em&gt;P&lt;/em&gt; = 0.008) showed significantly better results with shorter processing time in the VR group. In contrast, in the general cognitive assessment using the Montreal cognitive assessment (MoCA), although it showed better results in the VR group (MD = 1.45, 95% CI -0.20 – 3.09, &lt;em&gt;P&lt;/em&gt; = 0.08), the results were not significant. The meta-analysis showed homogeneous result in rote memory (I&lt;sup&gt;2&lt;/sup&gt; = 6%) and executive function (I&lt;sup&gt;2&lt;/sup&gt; = 0%) analyses. For general cognitive analysis the result was heterogeneous (I&lt;sup&gt;2&lt;/sup&gt; = 86%).&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;p&gt;Interventions using VR have shown promising results in improving rote memory and executive function, especially when VR intervention is combined with a motorized assistive devices. This combination therapy not only trains cognitive skills, but also trains the patient's motor skills simultaneously. For gener","PeriodicalId":72447,"journal":{"name":"Brain disorders (Amsterdam, Netherlands)","volume":"15 ","pages":"Article 100152"},"PeriodicalIF":0.0,"publicationDate":"2024-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666459324000374/pdfft?md5=45390282cb6e7f4e499ec157f6fa211f&pid=1-s2.0-S2666459324000374-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141638671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}